# تصميم وتشييد بعض مشتقات البيروليدين كاربوكسيلك ذات تأثير مضاد للتشنجات

رسالة مقدمة من محمود محمد جمال الدين محيى الدين

للحصول على درجة الماجستير فى العلوم الصيدلية (كيمياء صيدلية)

تحت إشراف

الأستاذ الدكتور محمد عبد الحميد اسماعيل أستاذ الكيمياء الصيدلية كلية الصيدلة – جامعة عين شمس

الأستاذ الدكتور محمد نبيل يوسف أبو العينين أستاذ الكيمياء الصيدلية المركز القومي للبحوث

كلية الصيدلة – جامعة عين شمس جمهورية مصر العربية . ٢٠١٠

## Molecular Modeling and Synthesis of Certain Substituted Pyrrolidine Carboxylic acids with Anticonvulsant Potential

Thesis
Presented By

# Mahmoud Mohamed Gamal Eldin Mohie Eldin Pharmacist in National Research Centre

B. Pharm.Sci
(AinShams University)
Submitted to the
Faculty of Pharmacy, Ain Shams University
In partial Fulfillment of the Requirement for the Degree
of Master of Pharmaceutical Science
In
Pharmaceutical Chemistry

Supervised by

#### Dr. M. Nabil Youssef Aboul-Enein

Prof. of Pharmaceutical Chemistry National Research Centre Cairo, Egypt

#### Dr. Mohamed AbdelHamid Ismail

Prof. of Pharmaceutical Chemistry
Faculty of Pharmacy, Ain Shams
University
Cairo, Egypt

#### Dr. Ola Ahmed Saleh

Researcher of Pharmaceutical Chemistry National Research Centre Cairo, Egypt

Faculty of Pharmacy Ain Shams University **2010** 

# Content

Acknowledgement	I
List of Abbreviations	III
List of tables	V
List of Figures	VI
Abstract	VII
Introduction	1
General Part	
I- Antiepileptic and Anticonvulsant Agents	5
II- Mechanism of Action of Antiepileptic Drugs	56
Special Part	
- Basis of the present investigation	61
- Schemes	72
- Theoretical Discussion	75
- Experimental	97
- Molecular Modeling	131
- Biological Evaluation	138
References	151
Arabic summery	١

#### Acknowledgement

First of all, I want to thank God, then to my parents for enlightening my path and strengthening my will to produce this work.

I am sincerely indebted and profoundly grateful to *Professor Dr. Mohamed Nabil Aboul-Enein*. Professor of Pharmaceutical Chemistry,

Department of Pharmaceutical Sciences, National Research Centre, for
the suggestion of the thesis subject as well as for his endless support,
guidance and unlimited valuable advice throughout this work.

I wish to express my thanks to *Professor Dr. Mohamed Abdel Hamid Ismail* Professor of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, for his valuable sponsorship and highly appreciated encouragement.

It is my pleasure to give my deepest appreciation and gratitude to *Professor Dr. Aida Abdel-Sattar El-Azzouny*, Professor of Pharmaceutical Chemistry, National Research Centre, for her encouragement, valuable instructions, comments and continuous support throughout this work.

Sincere thanks and appreciation are due to *Dr. Ola Ahmad Saleh*, Researcher of Pharmaceutical Chemistry, National Research Centre, for her efforts in helping and supporting me.

I would like to sieze this opportunity to thank *Professor Dr. Yousreya Aly Maklad*, Professor of Pharmacology, Department of Pharmaceutical Sciences, National Research Centre, for her great help,

valuble discussion and real support in performing the Pharmacological Evaluation.

Sincere thanks and appreciation are due to *Ass. Professor Dr Mohamed Ibrahim Attia*, Department of Pharmaceutical Sciences, National Research Centre, for his scientific advice.

I am also grateful of *Professor Dr. Mahmoud Nawwar*, Professor of Phytochemistry, Department of Phytochemistry and Plant Systematic, National Research Centre, for the assistance in NMR explanation.

Also, I am heartly grateful to all *my colleagues* at the Department of Pharmaceutical Sciences, National Research Centre for their friendly support and encouragement during this work.

My gratitude is dedicated to the *National Research Centre*. The institution to whom I belong and without his support in every respect, this work would not have seen the light.

My generous thanks to the *Department of Pharmaceutical*Chemistry Faculty of Pharmacy, Ain Shams University, for sponsoring my work.

#### **List of Abbreviations**

A<sup>o</sup> : Angström

**Ar** : Aryl

**b.p.** : boiling point

**br.** : broad

**b.wt.** : body weight

°C : Degree Celsius

calc. : Calculated

**CDCl**<sub>3</sub> : Deuterated chloroform

**Co.** : Company

δ : Chemical shift in parts per million downfield from

tetramethylsilane (NMR)

s : singlet

d : doublet

t : triplet

**q** : quartet

**DMSO** : Dimethylsulpoxide

 $\mathbf{ED}_{50}$  : Dose that is effective in 50% of the tested subjects

**El** : Electron impact

**Fig.** : Figure

**gm** : gram (s)

 $\mathbf{h}$  : hour (s)

IC<sub>50</sub>: Inhibitory concentration in 50% of the test subjects

IR : Infrared

**Lit.** : Literature

**LD**<sub>50</sub> : Lethal dose in 50% of the test subjects

**M**<sup>+</sup> : Molecular ion

m : multiplet

**min.** : minutes

**m.p.** : melting point

MS : Mass spectrometry

**FAB** : Fast Atom Bombardment.

m/z : mass to charge ratio

NMR : Nuclear Magnetic Resonance

**p** : page

**Pet. Ether** : Petroleum ether

**ppm** : parts per million

alc :alcoholic

### List of tables:

Table1	: Analytical data of series 8a-e.	109
Table 2	: Analytical data of series 9a-e.	114
Table 3	: Analytical data of series <i>13a-e</i> .	124
Table 4	: Analytical data of series 14a-e.	128
Table 5	: Data of docking study using Molsoft ICM 3.5 Module	132
Table 6	: Anticonvulsant activity of series 8a-e.	141
Table 7	: Anticonvulsant activity of series <i>9a-e</i> .	143
Table 8	: Anticonvulsant activity of series 13a-e.	145
Table 9	: Anticonvulsant activity of series <i>14a-e</i> .	147
Table 10	: Comparison between the anticonvulsant results and docking scores of the target compounds and those of Gabapentin.	149

## **List of Figures:**

Fig.1	:Sites of action of antiepileptic drugs.	59
Fig. 2	:Schematic diagram of biosynthesis and metabolism of GABA.	60
Fig. 3	:The structure of hBCATc-ox complexed with Gapapentin.	69
Fig. 4	:Schematic diagram showing hydrogen-bond and salt-bridge interactions of the active-site residues.	70
Fig. 5	:Molecular Modeling view of Gabapentin inside the binding site of GABA aminotransferase enzyme.	70

# Molecular Modeling and Synthesis of Certain Substituted Pyrrolidine Carboxylic acids with Anticonvulsant Potential

Thesis submitted by Mahmoud Mohamed Gamal Eldin, for the partial fulfillment of the degree of MSc. of Pharmaceutical Sciences (Pharmaceutical Chemistry), Ain Shams University (2010)

#### **Abstract:**

Molecular Modeling and synthesis of certain substituted pyrrolidine-3- carboxylic acids (8a-e, 9a-e, 13a-e and 14a-e) have been accomplished. The aim of their preparation is to evaluate their anticonvulsant activity.

Reviews on different classes of antiepileptic and anticonvulsant agents, the mechanism of action of antiepileptic drugs have been discussed.

A detailed discussion on the molecular design strategy and the synthesis of the designed compounds 8a-e, 9a-e, 13a-e and 14a-e as well as the starting materials and intermediates have been described and illustrated in Schemes I, II and III.

The starting materials, which have been synthesized throughout this work and reported in the literature are:

**1-** 2-(2-Cyanoethylamino)-3-phenylpropionic acid (2*a*).

- **2-** 2-(2-Cyanoethylamino)-3-(4-hydroxyphenyl)propionic acid (2b).
- **3-** Ethyl 2-(3-ethoxy-3-oxopropylamino)-3-phenylpropanoate (3a).
- **4-** Ethyl 2-(3-ethoxy-3-oxopropylamino)-3-(4-hydroxyphenyl)-propanoate (*3b*).
- **5-** Ethyl 2-(N-(3-ethoxy-3-oxopropyl)acetamido)-3-phenyl propanoate (*4a*).
- **6-** Ethyl 2-(N-(3-ethoxy-3-oxopropyl)acetamido)-3-(4-hydroxy-phenyl)propanoate (*4b*).
- **7-** Ethyl 2-(N-(3-ethoxy-3-oxopropyl)acetamido)-3-(4-methoxyphenyl) propanoate (*5b*).
- **8-** Ethyl 3-(4-ethoxyphenyl)-2-(N-(3-ethoxy-3-oxopropyl)acetamido) propanoate (*5c*).
- **9-** Ethyl 2-(N-(3-ethoxy-3-oxopropyl)acetamido) -3-(4-propoxyphenyl)propanoate (*5d*).
- **10-** Ethyl 3-(4-butoxyphenyl)-2-(N-(3-ethoxy-3-oxopropyl)acetamido) propanoate (*5e*).
- **11-** Ethyl 1-acetyl-5-benzyl -4-oxopyrrolidine-3-carboxylate (*6a*).
- **12-** Ethyl 1-acetyl-5-(4-methoxybenzyl)-4-oxopyrrolidine-3-carboxylate (*6b*).
- **13-** Ethyl 1-acetyl-5-(4-ethoxybenzyl)-4-oxopyrrolidine-3-carboxylate (*6c*).

- **14-** Ethyl 1-acetyl-4-oxo-5-(4-propoxybenzyl)pyrrolidine-3-carboxylate (*6d*).
- **15-** Ethyl 1-acetyl-5-(4-butoxybenzyl)-4-oxopyrrolidine-3-carboxylate (*6e*).
- **16-** Ethyl 1-Acetyl-5-benzyl-4-hydroxypyrrolidine-3-carboxylate (7*a*).
- **17-** Ethyl 1-Acetyl-4-hydroxy-5-(4-methoxybenzyl)pyrrolidine-3-carboxylate (*7b*).
- **18-** Ethyl 1-Acetyl-5-(4-ethoxybenzyl)-4-hydroxypyrrolidine-3-carboxylate (*7c*).
- **19-** Ethyl 1-Acetyl-4-hydroxy-5-(4-propoxybenzyl)pyrrolidine-3-carboxylate (*7d*).
- **20-** Ethyl 1-Acetyl-5-(4-butoxybenzyl)-4-hydroxypyrrolidine-3-carboxylate (*7e*).
- **21-** Ethyl 4-Acetoxy-1-acetyl-5-(4-methoxybenzyl)pyrrolidine-3-carboxylate (*10b*).
- **22-** Ethyl 1-Acetyl-5-(4-methoxybenzyl)-2,5-dihydro-1H-pyrrole-3-carboxylate (*11b*).
- **23-** Ethyl 1-Acetyl-5-(4-methoxybenzyl)pyrrolidine-3-carboxylate (*12b*).

**Abstract** 

This study comprises the synthesis of the following new intermediates:

- **1-** Ethyl 4-Acetoxy-1-acetyl-5-benzylpyrrolidine-3-carboxylate(*10a*).
- **2-** Ethyl 4-Acetoxy-1-acetyl-5-(4-ethoxybenzyl)-pyrrolidine-3-carboxylate (*10c*).
- **3-** Ethyl 4-Acetoxy-1-acetyl-5-(4-propoxybenzyl)-pyrrolidine-3-carboxylate (*10d*).
- **4-** Ethyl 4-Acetoxy-1-acetyl-5-(4-butoxybenzyl)-pyrrolidine-3-carboxylate (*10e*).
- **5-** Ethyl 1-Acetyl-5-benzyl-2,5-dihydro-1*H*-pyrrole-3-carboxylate (*11a*).
- **6-** Ethyl 1-Acetyl-5-(4-ethoxybenzyl)-2,5-dihydro-1*H*-pyrrole-3-carboxylate (*11c*).
- **7-** Ethyl 1-Acetyl-5-(4-propoxybenzyl)-2,5-dihydro-1*H*-pyrrole-3-carboxylate (*11d*).
- **8-** Ethyl 1-Acetyl-5-(4-butoxybenzyl)-2,5-dihydro-1*H*-pyrrole-3-carboxylate (*11e*).
- **9-** Ethyl 1-Acetyl-5-benzylpyrrolidine-3-carboxylate (*12a*).
- **10-** Ethyl 1-Acetyl-5-(4-ethoxybenzyl)pyrrolidine-3-carboxylate (*12c*).

- 11- Ethyl 1-Acetyl-5-(4-propoxybenzyl)pyrrolidine-3-carboxylate (*12d*).
- **12-** Ethyl 1-Acetyl-5-(4-butoxybenzyl)pyrrolidine-3-carboxylate (*12e*).

The synthesis of the target compounds, unsubstituted or substituted -5-aralkyl derivatives of 1-acetyl and deacetylated-4-hydroxy-5-benzyl and 5-(4-alkoxybenzyl)pyrrolidine-3-carboxylic acids (*8a-e*) and (*9a-e*) and 1-acetyl and deacetylated -5-benzyl and 5-(4-alkoxybenzyl) - pyrrolidine-3-carboxylic acids (*13a-e*) and (*14a-e*), were successfully achieved.

These designed compounds gave compatible microanalytical data. Their IR and Mass spectral data were in accordance with the assigned structures. Further, the <sup>1</sup>H NMR of compounds *8a-e*, *9b-e*, *13b-e* and *14c-e* and <sup>13</sup>C NMR of compounds *8c*, *9d*, *13e* and *14d*, taken as representative examples, have been recorded to confirm their structures.

The stereochemistry of compound 7b, taken as a representative example, has been studied and discussed. This might speculate the possible stereochemical structure of the compounds in series 7a-e, 8a-e, 9a-e, 12a-e, 13a-e and 14a-e.

The prepared target compounds are 8a-e, 9a-e, 13a-e and 14a-e:

1- 1-Acetyl-5-benzyl- 4-hydroxypyrrolidine-3-carboxylic acid (8*a*).

Abstract

- **2-** 1-Acetyl-4-hydroxy-5-(4-methoxybenzyl)pyrrolidine-3-carboxylic acid (*8b*).
- **3-** 1-Acetyl-5-(4-ethoxybenzyl)-4-hydroxypyrrolidine-3-carboxylic acid (*8c*).
- **4-** 1-Acetyl-4-hydroxy-5-(4-propoxybenzyl)pyrrolidine-3-carboxylic acid (*8d*).
- 5- 1-Acetyl-5-(4-butoxybenzyl)-4-hydroxypyrrolidine-3-carboxylic acid (*8e*).
- **6-** 5-Benzyl-4-hydroxypyrrolidine-3-carboxylic acid (*9a*).
- **7-** 4-Hydroxy-5- (4- methoxybenzyl)pyrrolidine-3-carboxylic acid (*9b*).
- **8-** 5-(4-Ethoxybenzyl)-4-hydroxypyrrolidine-3-carboxylic acid (*9c*).
- **9-** 4-Hydroxy-5-(4- propoxybenzyl)pyrrolidine-3-carboxylic acid (*9d*).
- **10-** 5-(4-Butoxybenzyl)-4-hydroxypyrrolidine-3-carboxylic acid (*9e*).
- **11-** 1-Acetyl-5-benzylpyrrolidine-3-carboxylic acid (*13a*).
- 12- 1-Acetyl-5-(4-methoxybenzyl)pyrrolidine-3-carboxylic acid (*13b*).
- 13- 1-Acetyl-5-(4-ethoxybenzyl)pyrrolidine-3-carboxylic acid (*13c*).